Evidence Table. Study Type: Randomized controlled trial. Study Aim: To compare frequent nocturnal hemodialysis and conventional in-center dialysis.
|
|
- Prosper O’Connor’
- 6 years ago
- Views:
Transcription
1 Evidence Table Clinical Area: Reference: Frequent home dialysis Culleton BF, Walsh M, Klarenbach SW et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life. JAMA 2007; 298: Study Type: Randomized controlled trial. Study Aim: To compare frequent nocturnal hemodialysis and conventional in-center dialysis. Outcomes Primary: Change in left ventricular mass over 6 months. Secondary: Blood pressure, anemia, mineral metabolism, quality of life. Design Number of subjects: N=52 (n=27 nocturnal hemodialysis; n=25 conventional hemodialysis) Description of study population: Nocturnal hemodialysis: mean age=55 years; 69% male; 88% white; mean time receiving dialysis=5.5 years: Conventional hemodialysis: mean age=53 years; 56% male; 84% white; mean time receiving dialysis=4.8 years. Inclusion criteria: At least 18 years old; receiving in-center, self-care or home hemodialysis 3 times a week; willing to train for and use nocturnal hemodialysis. Exclusion criteria: Lack physical or mental capacity for home nocturnal dialysis. Intervention: Patients were randomized to receive 1) standard hemodialysis: continued pre-randomization treatment 3 times a week: 2) nocturnal dialysis: incenter training 4-5 times a week for 2-6 weeks with direct nursing supervision and monitoring of biochemical parameters. After the training period, nocturnal hemodialysis was done at home without supervision, 5-6 nights a week for a minimum of 6 hours per night. Bellco Formula machines (Ontario, Canada) were used. Source of outcome data: Laboratory and imaging data (cardiovascular magnetic resonance for left ventricular mass); self-report data for quality of life. Length of follow-up: 6 months. Validity Blinding? Assessment of primary outcome was blinded. Appropriate randomization procedures? Yes. Appropriate comparison intervention? Yes. Treatment/control groups comparable at baseline? Yes. Other than intervention, was care/follow-up similar in each group? Yes. Adequate compliance with intervention? Yes. Sufficient statistical power? Yes, 95% power to detect a 10g difference in change in LV mass, 2-tailed alpha=0.05.
2 Intention to treat analysis? Modified. ITT approach for all patients with at least 1 baseline measurement (1 patient excluded). Completeness of follow-up: Primary endpoint assessed in 44 patients. Industry funding? None reported. Conclusions regarding validity of methods: Valid methods. Results Nocturnal Conventional Difference (n=26) (n=25) (95% CI), p-value Primary outcome LV mass, mean (SD), g Baseline (51.1) (92.3) Follow-up (45.2) (84.2) Change (23.0) 1.5 (24.0) (-29.6 to -1.0), <0.05 Selected secondary outcomes Blood pressure, mean (SD), mm Hg Systolic Baseline 129 (23) 135 (19) Follow-up 122 (23) 139 (20) Change -7 (29) 4 (17) -11 (-24 to 2), NS Diastolic Baseline 75 (14) 77 (16) Follow-up 68 (16) 75 (12) Change -7 (16) -2 (12) -5 (-13 to 2), NS Anemia Hemoglobin, mean (SD), g/dl Baseline 11.9 (1.2) 11.7 (1.3) Follow-up 11.6 (1.2) 11.8 (1.1) Change -0.3 (1.3) 0.1 (1.4) -0.4 (-1.2 to 0.3), NS Mineral metabolism Calcium, mean (SD) mg/dl Baseline 9.5 (0.6) 9.1 (1.2) Follow-up 9.4 (0.7) 8.9 (0.8) Change -0.1 (0.8) -0.2 (0.5) 0.1 (-0.3 to 0.4), NS Phosphate, mean (SD), mg/dl 1 Baseline 5.5 (1.5) 4.9 (1.3) Follow-up 4.4 (1.7) 5.3 (1.9) Change -1.1 (1.8) 0.4 (1.8) -1.5 (-2.5 to -0.5), <0.01 Quality of Life (mean EuroQol-5D index) 1 Normal range is mg/dl
3 Change (-0.07 to 0.17), NS Pre-selected dimensions, Kidney Disease QOL measure (0-100) NOTE: Baseline scores, change at follow-up Symptoms/problems (-3.8 to 11.2), NS Effects of kidney disease (2.0 to 15.2), 0.01 Burden of kidney disease (1.3 to 17.5), 0.02 Sleep (-10.2 to 5.0), NS
4 Adverse events, No. patients experiencing 1 event Nocturnal (n=26) Conventional (n=25) Bacteremia 4 4 Insertion or replacement of tunneled dialysis catheter 7 5 Vascular access angiogram 8 5 Vascular access surgical intervention 3 5 Authors Conclusions This preliminary study revealed that, compared with conventional hemodialysis (3 times weekly), frequent nocturnal dialysis improved left ventricular mass, reduced the need for blood pressure medications, improved some measures of mineral metabolism and improved selected measures of quality of life. Reviewer s Conclusions In this well-conducted RCT, the primary outcome, LV mass, significantly improved (was lower) in the group assigned to nocturnal home hemodialysis compared to conventional hemodialysis 3 times a week. There was also improvement in some secondary outcomes (phosphate level) but not others (anemia, calcium level). There was no between-group difference in overall quality of life. Two of four pre-selected kidney-related QOL dimensions signficantly improved in the nocturnal hemodialysis group, the other two did not differ signficantly between groups. The study may not have had sufficient power to detect differences in secondary outcomes and was not powered to detect a difference in mortality.
5 Evidence Table Clinical Area: Reference: Frequent home dialysis Bergman A, Fenton SSA, Richardson RMA, Chan CT. Reduction in cardiovascular related hospitalization with nocturnal home hemodialysis. Clin Nephrol 2008; 69: Study Type: Cohort (Prospective) Study Aim: To compare cardiovascular hospitalizations with conventional versus nocturnal home dialysis. Outcomes Primary: Composite: Dialysis-related or cardiovascular-related admissions Secondary: Change in hospitalizations, all cause; visits to emergency, biochemical parameters. Design Number of subjects: N=32 nocturnal hemodialysis, N=42 conventional hemodialysis. Description of study population: Nocturnal hemodialysis: mean age=43 years; 60% male; mean time on dialysis=9 years: Conventional hemodialysis: mean age=44 years; 64% male; mean time on dialysis=8 years. Eligibility criteria: Consecutive patients converted to nocturnal hemodialysis. Patients in the comparison intervention were matched to intervention patients by age (±5 years), gender, length of time on dialysis (± 2 years), diabetes status and comorbidities (modified Charlson Index) Exposure/Intervention: Conventional hemodialysis was given for 4 hours, 3 times a week. Nocturnal hemodialysis was given at home for 8-10 hours, 6 nights per week. Source of outcome data: Medical records, laboratory tests. Length of follow-up: 3 years (1 year before and 2 years after conversion to nocturnal hemodialysis). Validity Is the study type appropriate for the question(s) being asked? Randomization would be preferred. Population-based sample? No. Potential selection biases: None identified. Sufficient statistical power? Not discussed. Did an objective observer assess outcomes? Not discussed. Completeness of follow-up: 100%. Results adjusted for confounding factors? No, but there was matching based on comorbidity. Conclusions regarding validity of methods: Did not adjust for confounding factors in analysis.
6 Results Primary outcome: Dialysis-related or cardiovascular-related admissions (per patient year) Nocturnal Conventional Between-group p-value Hemodialysis Hemodialysis (n=32) (n=42) Baseline 0.50 ± ± 0.14 Follow-up* 0.17 ± ± 0.12 <0.05 * 2 years post-conversion to nocturnal hemodialysis for experimental group. Selected secondary outcomes, per patient year Nocturnal Hemodialysis (n=32) Conventional Hemodialysis (n=42) All-cause hospitalization Baseline 0.53 ± ± 0.17 Follow-up 0.21 ± ± 0.12 ER visits Baseline 1.03 ± ± 0.15 Follow-up 0.93 ± ± 0.15 Note: No statistically significant between group differences were reported. Authors Conclusions Conversion to NHD (nocturnal hemodialysis) is associated with a decrease in dialysis and cardiovascular-related hospital admission. The clinical and mechanistic relevance in uremic patients of improved phosphate and anemia management requires further evaluation. Reviewer s Conclusions In this prospective cohort study, there was a significantly greater reduction in dialysisrelated and/or cardiovascular-related hospital admissions in a group converted to nocturnal hemodialysis 6 times a week versus a group that remained on conventional dialysis 3 days a week. The study was not randomized so there may have been some differences between groups that affected outcomes.
7 Evidence Table Clinical Area: Reference: Frequent home dialysis Schwartz DI, Pierratos A, Richardson RMA et al. Impact of nocturnal home hemodialysis on anemia management in patients with end-stage renal disease. Clin Nephrol 2005; 63: Study Type: Cohort (Retrospective) Study Aim: To investigate whether nocturnal hemodialysis (NHD) would improve hemoglobin (Hb) concentrations and decrease requirements for erythropoietin (EPO) compared to conventional hemodialysis (CHD) in patients in patients with end-stage renal disease (ESRD). Outcomes Primary: Change in Hb and EPO dose, baseline and 6 and 12 months. Design Number of subjects: N=63 patients receiving nocturnal home dialysis; n=32 patients on conventional hemodialysis. Description of study population: Home dialysis group: Mean age=46 ± 2 years 67% male; CHD group: Mean age=57 ± 3 years 72% male. Eligibility criteria: Enrolled in the hospitals dialysis program for at least 6 months; all participants (including the comparison group) had to be eligible for the nocturnal dialysis program and stable in their anemia management. Control patients were matched to NHD patients by sex, baseline iron repletion status, EPO dose and midweek Hb concentrations. Exposure/Intervention: Nocturnal home dialysis: Hemodialysis at home for 6-8 hours, 5-6 nights a week. CHD: Hemodialysis 4 hours, 3 times a week. Source of outcome data: Retrospective chart review. Length of follow-up: Had to be followed for at least 6 months. Validity Is the study type appropriate for the question(s) being asked? Yes, a randomized trial is ideal. Population-based sample? Clinic based. Potential selection biases: All patients were eligible for NHD, but it is possible that those selected to actually receive it were sicker, or healthier than those who continued to receive conventional dialysis. Sufficient statistical power? Not discussed. Did an objective observer assess outcomes? Yes. Completeness of follow-up: NA, only included cases for which data were available. Results adjusted for confounding factors? Used matching. Conclusions regarding validity of methods: Limitations of the study design include the possibility of residual confounding and incomplete or inaccurate reporting in medical records.
8 Results Change in hemoglobin concentration and EPO dose Baseline 6 months 12 months NHD Hb (g/l) 115 ± ± ± 2.3* EPO dose (U/week) ± ± ± 1100** EPO-free (%) * CHD Hb (g/l) 110 ± ± ± 2.2 EPO dose (U/week) 8300 ± ± ± 1000 EPO-free (%) NHD=nocturnal hemodialysis; CHD=conventional hemodialysis *p-value <0.05 between CHD and NHD groups at 12 months ** p-value<0.05 within group, repeated measures Authors Conclusions Enhancing uremic clearance by NHD resulted in a rise in Hb and a fall in EPO requirement. Reviewer s Conclusions There was a statistically significantly greater increase in Hg and percentage of patients EPO-free at 12 months in the group receiving nocturnal home hemodialysis compared to conventional hemodialysis.
9 Evidence Table Clinical Area: Reference: Frequent home dialysis Blagg CR, Kjellstrand CM, Ting GO, Young BA. Comparison of survival between short-daily hemodialysis and conventional hemodialysis using the standardized mortality ratio. Hemodialysis International 2006; 10: Study Type: Case Series (statistical analysis) Study Aim: To compare survival in patients treated with short daily dialysis (at home or in-center) with national statistics on survival on conventional dialysis. Outcomes Primary: Survival. Design Number of subjects: N=117. Description of study population: 71 males/ 46 females; mean age=55.5 years (range=19 to 89 years); men time being treated for end-stage rnal diasese=5 years.. Eligibility criteria: Patients in the U.S. with end-stage renal disease who were treated with short-daily dialysis in Consecutive patients? Not discussed. Intervention: Short daily hemodialysis was defined as hemodialysis 5 or more times a week, for 2 to 3.5 hours per session. 19 (16%) were treated in-center using standard equipment, and 98 (94%) were treated at home using the PHD System (Aksys Ltd, USA). The study was a statistical analysis of mortality data using established techniques for calculating standardized mortality rates. Source of outcome data: Medical records. Length of follow-up: Up to 2 years. Validity Was population homogenous? Reasonably. Potential selection biases: Patients who volunteered for, or were selected for home daily dialysis may have been healthier than patients receiving in-center dialysis. Did an objective observer assess outcomes? NA, used medical records and objective outcome. Outcomes were compared to national mortality rats, as reproted in the United States Renal Data Systems (USRDS). Appropriate analysis: Appeared to be, cited references for their statistical methods. Industry funding? Yes, funding by Aksys, and first author is consultant to Aksys. Conclusions regarding validity of methods: This was a statistical analysis of data from patient medical records and the USRDS. Involvement from the manufacturer of the home dialysis device may have introduced bias.
10
11 Results Number of expected deaths over 2 years (statistical analysis) 25.7 (95% CI= ) Adjusted for age, sex, race and diagnosis Actual number of deaths=10 Standard mortality ratio=0.39 (95% CI= ), p<0.005 (Comparison with national mortality rates, patients receiving conventional dialysis). Authors Conclusions daily hemodialysis patients had a 61% better survival. Patients treated by short-daily hemodialysis have a better survival rate than comparable populations treated by conventional hemodialysis). Reviewer s Conclusions The analysis found a statistically significantly better survival in patients who received short daily dialysis, mainly at home, than patients receiving conventional dialysis. Industry funding may have led to bias, and there may be limits to the statistical technique of calculating standardized mortality ratios (SMR).
12 Evidence Table Clinical Area: Reference: Frequent home dialysis Mahadevan K, Pellicano R, Reid A et al. Comparison of biochemical, hematological and volume parameters in two treatment schedules of nocturnal home hemodialysis. Nephrology 2006; 11: Study Type: Cohort (Retrospective) Study Aim: To compare two schedules of nocturnal home dialysis. Outcomes Primary: Biochemical parameters 3-6 months after starting nocturnal dialysis. Design Number of subjects: N=13 six nights/week, N=21 alternate nights Description of study population: Six nights a week: mean age=52 years; 13 males/ 0 females; mean time on dialysis=29 months: every other night: mean age=45 years; 18 males/ 3 females; mean time on dialysis=33 months. Eligibility criteria: Patients stable on home dialysis for three months or longer; patients of dialysis programs at one of two hospitals in Australia. Exposure/Intervention: Nocturnal dialysis 8 hours per night in the supine posture. Patients in the program at Geelong Hospital had dialysis 6 nights a week, and patients at Monash Medical Center had dialysis every other night. Source of outcome data: Serum samples. Length of follow-up: 3-6 months. Validity Is the study type appropriate for the question(s) being asked? An RCT or prospective cohort study would be preferable. Population-based sample? No. Potential selection biases: Patients on nocturnal dialysis 6 nights a week were slightly older; otherwise groups were similar. No obvious selection biases. Sufficient statistical power? Not reported. Did an objective observer assess outcomes? Objective tests. Completeness of follow-up: Retrospective, so included patients with data. Results adjusted for confounding factors? No. Conclusions regarding validity of methods: Limitations include not adjusting for pre-intervention values in the analysis and multiple outcomes without adjustment of the significance level. A limitation of the study design is that, without randomization, there may be baseline differences between groups that affect outcomes.
13 Results Parameters 6 nights/week Every other night p-value (n=13) (n=21) Urea (mmol/l) Pre ± ± 7.06 <0.001 Post 2.32 ± ± Creatinine (umol/l) Pre 437 ± ± 204 <0.001 Post 140 ± ± 84 <0.001 Phosphate (mmol/l) Pre 1.64 ± ± Post 0.86 ± ± Calcium (mmol/l) Pre 2.57 ± ± 0.19 <0.002 Post 2.60 ± ± PTH (pmol/l) (median) Pre NS Post (3 months) Hemoglobin (g/l) 123 ± ± 16 NS Albumin (g/l) 38.3 ± ± 4.5 NS Homocysteine (mmol/l) 12.4 ± ± 3.2 NS UFR (ml/min) 249 ± ± 168 <0.002 Weight gain (kg) 2.0 ± ± PTH=parathyroid hormone; UFR=ultrafiltration rate Medication use, n (%) 6 nights/week Every other night p-value (n=13) (n=21) Phosphate binders 0 8 (38) NS Calcitrol 11 (85) 11 (52) NS BP medications 6 (46) 4 (19) NS Erythropoietin 10 (77) 18 (86) NS Authors Conclusions (nocturnal dialysis 6 nights a week) offers the optimum biochemical, volume and clinical outcome, but (nocturnal dialysis every other night) has additional appeal to providers seeking home-based cost advantages and consumable expenditure control.
14 Reviewer s Conclusions After 3-6 months on nocturnal dialysis, there were significant differences between groups in certain parameters (urea, creatinine and PTH) but not others (phosphate, calcium, albumin, homocystine). Urea, creatinine and PTH levels were all significantly lower in the group treated 6 nights/week. There were no significant differences at follow-up in the proportion of patients taking phosphate blinders, calcitrol, blood pressure medications or erythropoietin. The study was likely underpowered to detect differences in medication use, and some of the post-treatment differences in biological parameters may have been due to differences in pre-treatment values..
All patients suitable for home dialysis should do PD first
All patients suitable for home dialysis should do PD first 2008 BC Nephrology Day Conference October 2, 2008 Vancouver, British Columbia Robert S. Lockridge, Jr. M.D. Lynchburg Nephrology Physicians Associate
More informationStarting with Home Dialysis. Budapest Nephrology School 2016 Ágnes Haris MD, PhD, Kálmán Polner MD St. Margit Hospital, Budapest
Starting with Home Dialysis Budapest Nephrology School 2016 Ágnes Haris MD, PhD, Kálmán Polner MD St. Margit Hospital, Budapest Major concept of the RRT modality selection Hemodialysis Peritoneal dialysis
More informationIndividual Study Table Referring to Part of Dossier: Volume: Page:
Synopsis Abbott Laboratories Name of Study Drug: Paricalcitol Capsules (ABT-358) (Zemplar ) Name of Active Ingredient: Paricalcitol Individual Study Table Referring to Part of Dossier: Volume: Page: (For
More informationComing to a Home near You
Home Dialysis i Coming to a Home near You John A. Sweeny NANT Annual National Symposium Tuesday March 8 th, 2011 Initial Home Hemodialysis Home HD was begun to reduce the cost of in-hospital HD in the
More informationINFLUENCE OF LOW PROTEIN DIET IN IMPROVING ANEMIA TREATED WITH ERYTHROPOETIN
INFLUENCE OF LOW PROTEIN DIET IN IMPROVING ANEMIA TREATED WITH ERYTHROPOETIN, Idrizi A, Barbullushi M, Gjyzari A, Duraku A Department of Nephrology, University Hospital Center, Tirana, Albania Introduction
More informationWHEN (AND WHEN NOT) TO START DIALYSIS. Shahid Chandna, Ken Farrington
WHEN (AND WHEN NOT) TO START DIALYSIS Shahid Chandna, Ken Farrington Changing Perspectives Beta blockers 1980s Contraindicated in heart failure Now mainstay of therapy HRT 1990s must Now only if you have
More informationPatients and Machines. NANT Annual National Symposium Wednesday March 9 th, 2011
Patients and Machines John A Sweeny John A. Sweeny NANT Annual National Symposium Wednesday March 9 th, 2011 Caroline Helm Caroline Helm was the first homepatient in the United States. She was a patient
More informationHTA ET DIALYSE DR ALAIN GUERIN
HTA ET DIALYSE DR ALAIN GUERIN Cardiovascular Disease Mortality General Population vs ESRD Dialysis Patients 100 Annual CVD Mortality (%) 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age
More informationi. Where is the participant seen?
PFU01 method used: Phone/in-person interview 1 Enter PIP # here: Online survey 2 Enter Web # here: Initials of person completing form: Date Form Completed: / / Form Version: 03 / 01 / 18 Is the participant
More informationHome Hemodialysis or Transplantation of the Treatment of Choice for Elderly?
Home Hemodialysis or Transplantation of the Treatment of Choice for Elderly? Miklos Z Molnar, MD, PhD, FEBTM, FERA, FASN Associate Professor of Medicine Division of Nephrology, Department of Medicine University
More informationmean hemoglobin 11 g/dl (110 g/l) compared to patients with lower mean hemoglobin values (Table 20).
S44 Figure 53 depicts the trend in Epoetin dosing from the 1998 study period to the 2003 study period, with an increasing mean weekly Epoetin dose (units/kg/wk) for patients prescribed Epoetin in lower
More informationAdvances in Peritoneal Dialysis, Vol. 29, 2013
Advances in Peritoneal Dialysis, Vol. 29, 2013 Takeyuki Hiramatsu, 1 Takahiro Hayasaki, 1 Akinori Hobo, 1 Shinji Furuta, 1 Koki Kabu, 2 Yukio Tonozuka, 2 Yoshiyasu Iida 1 Icodextrin Eliminates Phosphate
More informationGeriatric Nutritional Risk Index, home hemodialysis outcomes 131
Subject Index Aksys PHD system 113 Anemia, home outcomes 111, 172, 173 Automated peritoneal dialysis dialysis comparison 17, 18 selection factors 18, 19 telemedicine system 19 21 Blood pressure -peritoneal
More informationASN DIALYSIS ADVISORY GROUP ASN DIALYSIS CURRICULUM
ASN DIALYSIS ADVISORY GROUP ASN DIALYSIS CURRICULUM Medical Management of Home Hemodialysis Patients Brent W. Miller, MD Professor of Medicine Washington University School of Medicine Saint Louis, Missouri
More informationPrescriptions for Home Hemodialysis
9 Prescriptions for Home Hemodialysis Robert Lockridge, MD 1 Tom Cornelis, MD 2 Carolyn van Eps, MBBS, PhD, FRACP 3 1 Lynchburg Nephrology Physicians, Lynchburg, Virginia, USA; 2 Department of Internal
More informationHEALTHYSTART TRAINING MANUAL. Living well with Kidney Disease
HEALTHYSTART TRAINING MANUAL Living well with Kidney Disease KIDNEY DISEASE CAN AFFECT ANYONE! 1 HEALTHYSTART PROGRAMME HEALTHYSTART is a lifestyle management programme to assist you to remain healthy
More informationQuality of sleep in patients with chronic kidney disease
Nephrol Dial Transplant (2004) 19: 95 99 DOI: 10.1093/ndt/gfg423 Original Article Quality of sleep in patients with chronic kidney disease Eduard A. Iliescu, Karen E. Yeates and David C. Holland Department
More informationChronic kidney disease (CKD) has received
Participant Follow-up in the Kidney Early Evaluation Program (KEEP) After Initial Detection Allan J. Collins, MD, FACP, 1,2 Suying Li, PhD, 1 Shu-Cheng Chen, MS, 1 and Joseph A. Vassalotti, MD 3,4 Background:
More informationState Profile for FY 2018 for Dialysis Patients and Facilities - STATE SAMPLE
Dear State Surveyor: State Profile for FY 2018 for Dialysis Patients and Facilities - STATE SAMPLE This report is designed to provide a comparative summary of treatment patterns and patient outcomes for
More informationApplying clinical guidelines treating and managing CKD
Applying clinical guidelines treating and managing CKD Develop patient treatment plan according to level of severity. Source: Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012
More informationIrish Practice Nurses Association Annual Conference Tullamore Court Hotel OCTOBER 6 th 2012
Irish Practice Nurses Association Annual Conference Tullamore Court Hotel OCTOBER 6 th 2012 Susan McKenna Renal Clinical Nurse Specialist Cavan General Hospital Renal patient population ACUTE RENAL FAILURE
More informationOxford Kidney Unit What do my blood and dialysis results mean? Information for patients
Oxford Kidney Unit What do my blood and dialysis results mean? Information for patients page 2 If you are on haemodialysis (HD) or peritoneal dialysis (PD) this leaflet is for you. It will provide you
More informationIn-Center Hemodialysis Six Times per Week versus Three Times per Week
Journal Club du 25 novembre 2010 In-Center Hemodialysis Six Times per Week versus Three Times per Week The FHN Trial Group N Engl J Med 2010 Frequent Hemodialysis Network Introduction fréquence? dose?
More informationEfficacy and tolerability of oral Sucrosomial Iron in CKD patients with anemia. Ioannis Griveas, MD, PhD
Efficacy and tolerability of oral Sucrosomial Iron in CKD patients with anemia Ioannis Griveas, MD, PhD Anaemia is a state in which the quality and/or quantity of circulating red blood cells are below
More informationAna Paula Bernardo. CHP Hospital de Santo António ICBAS/ Universidade do Porto
Ana Paula Bernardo CHP Hospital de Santo António ICBAS/ Universidade do Porto Clinical relevance of hyperphosphatemia Phosphate handling in dialysis patients Phosphate kinetics in PD peritoneal phosphate
More informationNATIONAL QUALITY FORUM Renal EM Submitted Measures
NATIONAL QUALITY FORUM Renal EM Submitted Measures Measure ID/ Title Measure Description Measure Steward Topic Area #1662 Percentage of patients aged 18 years and older with a diagnosis of CKD ACE/ARB
More informationChapter Two Renal function measures in the adolescent NHANES population
0 Chapter Two Renal function measures in the adolescent NHANES population In youth acquire that which may restore the damage of old age; and if you are mindful that old age has wisdom for its food, you
More informationFOUR. Clinical Indicators of Care
Clinical Indicators of Care T FOUR The great questions of the time are not decided by speeches and majority decisions but by iron and blood. Otto von Bismarck, Speech to the Prussian Diet 78 ž 2000 ATLAS
More informationPublished trials point to a detrimental relationship
ANEMIA, CHRONIC KIDNEY DISEASE, AND CARDIOVASCULAR DISEASE: THE CLINICAL TRIALS Steven Fishbane, MD* ABSTRACT Clinical trials have shown a strong detrimental relationship among anemia, chronic kidney disease
More informationEffects of Kidney Disease on Cardiovascular Morbidity and Mortality
Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Joachim H. Ix, MD, MAS Assistant Professor in Residence Division of Nephrology University of California San Diego, and Veterans Affairs
More informationLesson #7: Quality Assessment and Performance Improvement
ESRD Update: Transitioning to New ESRD Conditions for Coverage Student Manual Lesson #7: Quality Assessment and Performance Improvement Learning Objectives At the conclusion of this lesson, you will be
More informationThe hypertensive kidney and its Management
The hypertensive kidney and its Management Dr H0 Chung Ping Hypertension Management Seminar 20061124 Hypertensive kidney Kidney damage asymptomatic till late stage Viscous cycle to augment renal damage
More informationComparison of Erythropoietin and Darbepoetin in Chronic Kidney Disease Patients in a Tertiary Care Hospital
Human Journals Research Article July 2017 Vol.:9, Issue: 4 All rights are reserved by Pournami A S et al. Comparison of Erythropoietin and Darbepoetin in Chronic Kidney Disease Patients in a Tertiary Care
More informationAnalytical Methods: the Kidney Early Evaluation Program (KEEP) The Kidney Early Evaluation program (KEEP) is a free, community based health
Analytical Methods: the Kidney Early Evaluation Program (KEEP) 2000 2006 Database Design and Study Participants The Kidney Early Evaluation program (KEEP) is a free, community based health screening program
More informationStatus of the CKD and ESRD treatment: Growth, Care, Disparities
Status of the CKD and ESRD treatment: Growth, Care, Disparities United States Renal Data System Coordinating Center An J. Collins, MD FACP Director USRDS Coordinating Center Robert Foley, MB Co-investigator
More informationStephen G. Worthley 1, Gerard T. Wilkins 2, Mark W. Webster 3,Joseph K. Montarello 1, Paul T. Antonis 4, Robert J. Whitbourn 5, Roderic J.
Six Month Results of First-in-Human Sympathetic Renal Artery Denervation Using a Next Generation Multi-Electrode Renal Artery Denervation System in Patients with Drug-Resistant Hypertension Stephen G.
More informationNephrology. Renal Replacement in End-Stage Renal Disease Patients over 75 Years Old. ABC Fax
American Journal of Nephrology Original Article: Basic Sciences Am J Nephrol 2003;23:7 77 DOI: 0.59/000068040 Received: July 23, 2002 Accepted: October 2, 2002 Renal Replacement in End-Stage Renal Disease
More information2.0 Synopsis. ABT-358 M Clinical Study Report R&D/06/099. (For National Authority Use Only) to Item of the Submission: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Zemplar Injection Name of Active Ingredient: Paricalcitol Individual Study Table Referring to Item of the Submission: Volume: Page: (For National Authority
More informationPrevalence of cardiovascular damage in early renal disease
Nephrol Dial Transplant 2001) 16 wsuppl 2x: 7±11 Prevalence of cardiovascular damage in early renal disease Adeera Levin University of British Columbia, Renal Insuf ciency Clinic, Vancouver, Canada Abstract
More informationPhosphate Management Guideline for Patients Receiving Extended Duration Hemodialysis
IAMHD HOME HEMODIALYSIS CLINICAL PRACTICE STANDARDS AND PROCEDURES Phosphate Management Guideline for Patients Receiving Extended Duration Hemodialysis PRINTED copies of Clinical Practice Standards and
More informationPeer Review Report. [erythropoietin-stimulating agents]
21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report [erythropoietin-stimulating agents] (1) Does the application adequately address the issue of the public health need
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Level of renal function at which to initiate dialysis GUIDELINES
Level of renal function at which to initiate dialysis Date written: September 2004 Final submission: February 2005 GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR
More informationChapter Five Clinical indicators & preventive health
Chapter Five Clinical indicators & preventive health The painter who draws merely by practice and by eye, without any reason, is like a mirror which copies every thing placed in front of it without being
More informationHome Dialysis. Peritoneal Dialysis. Home Hemodialysis
Home Dialysis The information provided is not intended to be a substitute for professional medical advice. A licensed healthcare professional should be consulted for diagnosis and treatment of any and
More informationPrevalence of Access Recirculation in Prevalent Arterio-Venous (A-V) Fistula Hemodialysis Patients and Its Effect on Hemodialysis Adequacy
The Egyptian Journal of Hospital Medicine (July 2018) Vol. 72 (6), Page 4602-4609 Prevalence of Access Recirculation in Prevalent Arterio-Venous (A-V) Fistula Hemodialysis Patients and Its Effect on Hemodialysis
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Protein Restriction to prevent the progression of diabetic nephropathy GUIDELINES
Protein Restriction to prevent the progression of diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. A small volume of evidence suggests
More information8 th Annual Congress of the Bangladesh Society of Medicine Dhaka, Bangladesh March 23-24, Jeffrey P. Harris MD, FACP
8 th Annual Congress of the Bangladesh Society of Medicine Dhaka, Bangladesh March 23-24, 2008 The Internist and the Pre-End Stage Renal Disease Patient Jeffrey P. Harris MD, FACP Country: Bangladesh Population:
More informationKIDNEY DIALYSIS FOUNDATION ANNUAL REPORT PERITONEAL DIALYSIS PROGRAMME
KIDNEY DIALYSIS FOUNDATION ANNUAL REPORT PERITONEAL DIALYSIS PROGRAMME 2011 Prepared by Dr Grace Medical Director With input from: Lay Kwee Chin Senior Nurse Clinician, Patient Services Theresa Soh Clinical
More informationHome Hemodialysis: Key Trends and Advancements
Home Hemodialysis: Key Trends and Advancements 1 Today we ll discuss Trends influencing a movement towards increased use of more frequent, home hemodialysis (HHD) Clinical and patient QOL benefits of HHD
More informationEBM: Therapy. Thunyarat Anothaisintawee, M.D., Ph.D. Department of Family Medicine, Ramathibodi Hospital, Mahidol University
EBM: Therapy Thunyarat Anothaisintawee, M.D., Ph.D. Department of Family Medicine, Ramathibodi Hospital, Mahidol University How to appraise therapy literature Are the result valid? What are the result?
More informationADVANCES. Annual reports from the Centers for. In Anemia Management. Anemia Management in the United States: Is There Opportunity for Improvement?
ADVANCES Vol. 1 No.1 22 We are pleased to introduce our newest NPA publication, Advances in Anemia Management. This quarterly publication will address contemporary issues relating to the treatment of anemia
More informationNarender Goel et al. Middletown Medical PC, Montefiore Medical Center & Albert Einstein College of Medicine, New York
Narender Goel et al. Middletown Medical PC, Montefiore Medical Center & Albert Einstein College of Medicine, New York 4th International Conference on Nephrology & Therapeutics September 14, 2015 Baltimore,
More informationHaemodialysis Blood Results
Haemodialysis Blood Results Delivering the best in care UHB is a no smoking Trust To see all of our current patient information leaflets please visit www.uhb.nhs.uk/patient information leaflets.htm Introduction
More informationPredictors of Patient Survival in Continuous Ambulatory Peritoneal Dialysis 10-Year Experience in 2 Major Centers in Tehran
Dialysis Predictors of Patient Survival in Continuous Ambulatory Peritoneal Dialysis 10-Year Experience in 2 Major Centers in Tehran Monir Sadat Hakemi, 1 Mehdi Golbabaei, 2 Amirahmad Nassiri, 3 Mandana
More informationPublished trials point to a detrimental relationship
ANEMIA, CHRONIC KIDNEY DISEASE, AND CARDIOVASCULAR DISEASE: THE CLINICAL TRIALS Steven Fishbane, MD* ABSTRACT Clinical trials have shown a strong detrimental relationship among anemia, chronic kidney disease
More informationOn Referral to our Unit
Case Presentation By Samah Ibrahim Abdel Meguid Idris, MD Internal Medicine & Nephrology Consultant Head of Hemodialysis Unit Ahmed Maher Hospital, Alexandria Patient Data MEA 27-year-old male patient
More informationSecondary Hyperparathyroidism: Where are we now?
Secondary Hyperparathyroidism: Where are we now? Dylan M. Barth, Pharm.D. PGY-1 Pharmacy Resident Mayo Clinic 2017 MFMER slide-1 Objectives Identify risk factors for the development of complications caused
More informationVIHA Program Showcase - Tender is The Night
VIHA Program Showcase - Tender is The Night Julia Caryk, RN, CNE VIHA Renal Program Dr. Michael Schachter, MD, Medical Lead VIHA In-Centre Hemodialysis Program Live Poll Question! Could you personally
More informationLab Values Explained. working at full strength. Other possible causes of an elevated BUN include dehydration and heart failure.
Patient Education Lab Values Explained Common Tests to Help Diagnose Kidney Disease Lab work, urine samples and other tests may be given as you undergo diagnosis and treatment for renal failure. The test
More informationFluid Resuscitation in Critically Ill Patients with Acute Kidney Injury (AKI)
Fluid Resuscitation in Critically Ill Patients with Acute Kidney Injury (AKI) Robert W. Schrier, MD University of Colorado School of Medicine Denver, Colorado USA Prevalence of acute renal failure in Intensive
More informationWhy NxStage? 4th self-care dialysis symposium 6th & 7th June 2018 Brussels. Page 1
Why NxStage? 4th self-care dialysis symposium 6th & 7th June 2018 Brussels Page 1 Are you prepared? 4.1% Annual increase 1 in European dialysis patients Reference: 1. 2017 USRDS Annual Data Report Reference
More informationTHE HEMODIALYSIS PRESCRIPTION: TREATMENT ADEQUACY GERALD SCHULMAN MD VANDERBILT UNIVERSITY MEDICAL SCHOOL NASHVILLE, TENNESSEE
THE HEMODIALYSIS PRESCRIPTION: TREATMENT ADEQUACY GERALD SCHULMAN MD VANDERBILT UNIVERSITY MEDICAL SCHOOL NASHVILLE, TENNESSEE THE DIALYSIS CYCLE /TIME DESIGN OF THE NATIONAL COOPERATIVE DIALYSIS STUDY
More informationANEMIA & HEMODIALYSIS
ANEMIA & HEMODIALYSIS The anemia of CKD is, in most patients, normocytic and normochromic, and is due primarily to reduced production of erythropoietin by the kidney and to shortened red cell survival.
More informationCKD FOR INTERNISTS. Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College
CKD FOR INTERNISTS Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College INTRODUCTION In 2002, the National Kidney Foundation s Kidney Disease Outcomes Quality Initiative(KDOQI)
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Serum phosphate GUIDELINES
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Serum phosphate GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions
More informationIntermittent low dose digoxin may be effective and safe in patients with chronic heart failure undergoing maintenance hemodialysis
EXPERIMENTAL AND THERAPEUTIC MEDICINE 8: 1689-1694, 2014 Intermittent low dose digoxin may be effective and safe in patients with chronic heart failure undergoing maintenance hemodialysis XIAOZHAO LI 1,
More informationThe Egyptian Journal of Hospital Medicine (October 2017) Vol.69(1), Page
The Egyptian Journal of Hospital Medicine (October 2017) Vol.69(1), Page 1589-1594 Using Serum Beta Trace Protein to Estimate Residual Kidney Function in Hemodialysis Patients Hesham M. El-Sayed, Hussein
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationpatient characteriuics Chapter Two introduction 58 increasing complexity of the patient population 60 epo use & anemia in the pre-esrd period 62
introduction 58 < increasing complexity of the patient population 6 < epo use & anemia in the pre-esrd period 62 < biochemical & physical characteristics at initiation 64 < estimated gfr at intiation &
More informationSYNOPSIS. Issue Date: 04 February 2009 Document No.: EDMS -USRA
SYNOPSIS Issue Date: 04 February 2009 Document No.: EDMS -USRA-10751204 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Johnson & Johnson Pharmaceutical Research & Development,
More informationSUPPLEMENTARY DATA. Supplementary Table S1. Clinical characteristics of the study subjects.*
Supplementary Table S1. Clinical characteristics of the study subjects.* T2D ND n (F/M) 66 (21/45) 25 (7/18) Age (years) 61.8 ± 6.9 49.4 ± 7.3 # Body weight (kg) 95 ± 16 105 ± 13 # Body mass index (kg.
More informationJai R adhakrishnan, Radhakrishnan, MD Columbia University
Jai Radhakrishnan, MD Jai Radhakrishnan, MD Columbia University 1. The Patient-Centered Medical Home 2. CKD Clinic as the paradigm for PCMH? 3. Outcome data 4. The Columbia model 5. Limitations 6. Financial
More informationCalcium Management for Patients Receiving Extended Duration Hemodialysis
Calcium Management for Patients Receiving Extended Duration Hemodialysis Created November 2017; Updated March 2018 Approved by the BCPRA Home Hemodialysis Committee Table of Contents 1.0 Practice Standard...1
More informationHaemodiafiltration - the case against. Prof Peter G Kerr Professor/Director of Nephrology Monash Health
Haemodiafiltration - the case against Prof Peter G Kerr Professor/Director of Nephrology Monash Health Know your opposition.. Haemodiafiltration NB: pre or post-dilution What is HDF how is it different
More informationPERITONEAL DIALYSIS CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2006
PERITONEAL DIALYSIS CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2006 PATIENT IDENTIFICATION [Before completing please read instructions at the bottom of this page and on pages 5 and 6] MAKE CORRECTIONS
More informationThe Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009
The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009 Teresa Northcutt, RN BSN Primaris Program Manager, Prevention - CKD MO-09-01-CKD This material was prepared by Primaris,
More informationTrial to Reduce. Aranesp* Therapy. Cardiovascular Events with
Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,
More informationAcknowledgements. National Kidney Foundation of Connecticut Mark Perazella. Co-PI Slowing the progression of chronic kidney disease to ESRD
A Practical Approach to Chronic Kidney Disease Management for the Primary Care Practioner: A web-site sponsored by the National Kidney Foundation of Connecticut Robert Reilly, M.D. Acknowledgements National
More information2.0 Synopsis. Paricalcitol Capsules M Clinical Study Report R&D/15/0380. (For National Authority Use Only)
2.0 Synopsis AbbVie Inc. Name of Study Drug: ABT-358/Zemplar (paricalcitol) Capsules Name of Active Ingredient: paricalcitol Individual Study Table Referring to Part of Dossier: Volume: Page: (For National
More informationAcute Kidney Injury (AKI) How Wise is Early Dialysis in Critically Ill Patients? Modalities of Dialysis
Acute Kidney Injury (AKI) How Wise is Early Dialysis in Critically Ill Patients? A common condition in ICU patients Associated with high mortality and morbidity Renal Replacement Therapy (RRT) is the cornerstone
More informationThe Effect of Residual Renal Function at the Initiation of Dialysis on Patient Survival
ORIGINAL ARTICLE DOI: 10.3904/kjim.2009.24.1.55 The Effect of Residual Renal Function at the Initiation of Dialysis on Patient Survival Seoung Gu Kim 1 and Nam Ho Kim 2 Department of Internal Medicine,
More informationANNEX FORM TO EXAMINE THE CAUSES OF ESRD I IDENTIFICATION. 1 Record number (patient chart) Name. 1.1 Date of birth / / 1.2 Sex:
Supplementary Material from Prevalence of clinically validated primary causes of end-stage renal disease (ESRD) in a State Capital in Northeastern Brazil ANNEX FORM TO EXAMINE THE CAUSES OF ESRD I IDENTIFICATION
More informationCardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center
Cardiovascular Disease in CKD Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center Objectives Describe prevalence for cardiovascular disease in CKD
More informationS150 KEEP Analytical Methods. American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153
S150 KEEP 2009 Analytical Methods American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153 S151 The Kidney Early Evaluation program (KEEP) is a free, communitybased health screening
More informationEFFECT OF ONLINE HAEMODIAFILTRATION ON ALL- CAUSE MORTALITY AND CARDIOVASCULAR OUTCOMES Ercan Ok, Izmir, Turkey
EFFECT OF ONLINE HAEMODIAFILTRATION ON ALL- CAUSE MORTALITY AND CARDIOVASCULAR OUTCOMES Ercan Ok, Izmir, Turkey Chair: Walter H. Hörl, Vienna, Austria Wojciech Zaluska, Lublin, Poland Prof Ercan Ok Division
More informationYou can sleep while I dialyze
You can sleep while I dialyze Nocturnal Peritoneal Dialysis Dr. Suneet Singh Medical Director, PD, VGH Division of Nephrology University of British Columbia Acknowledgements Melissa Etheridge You can sleep
More informationGuest Speaker Evaluations Viewer Call-In Thanks to our Sponsors: Phone: Fax: Public Health Live T 2 B 2
Public Health Live T 2 B 2 Chronic Kidney Disease in Diabetes: Early Identification and Intervention Guest Speaker Joseph Vassalotti, MD, FASN Chief Medical Officer National Kidney Foundation Thanks to
More informationThe natural history of coronary calcification progression in a cohort of nocturnal haemodialysis patients
Nephrol Dial Transplant (2006) 21: 1407 1412 doi:10.1093/ndt/gfl021 Advance Access publication 27 February 2006 Brief Report The natural history of coronary calcification progression in a cohort of nocturnal
More informationAndrea Pizutti, LCSW Gayle Hall, BSN, RN, CNN Regional Operations Director Area Director Davita NxStage Kidney Care
Andrea Pizutti, LCSW Regional Operations Director Davita Gayle Hall, BSN, RN, CNN Area Director NxStage Kidney Care 1 Compare and contrast Home Dialysis Therapies Describe the End Stage Renal Disease patient
More informationBlood Pressure Measurement and Left Ventricular Mass Index in Hemodialysis Patients Comparison of Several Methods
DIALYSIS Blood Pressure Measurement and Left Ventricular Mass Index in Hemodialysis Patients Comparison of Several Methods Amir Ahamd Nassiri, 1 Legha Lotfollahi, 2,3 Neda Behzadnia, 4 Ilad Alavi Darazam,
More informationEffective Health Care
Number 3 Effective Health Care Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment Executive Summary Background Anemia (deficiency of red blood
More informationExamining Facility Level Data
Examining Facility Level Data for the USRDS Yi Li, PhD Professor of Biostatistics, University of Michigan, Ann Arbor Director, Kidney Epidemiology and Cost Center (KECC) Co Deputy Director, United States
More informationKIDNEY DIALYSIS FOUNDATION ANNUAL REPORT MEDICAL (P.D.)
KIDNEY DIALYSIS FOUNDATION ANNUAL REPORT MEDICAL (P.D.) 2005 Prepared by Dr Grace Lee Medical Director With input from: Theresa Soh Manager, Patient Services Wu Sin Yan Charge Nurse TABLE OF CONTENTS 1.
More informationIN-CENTER HEMODIALYSIS (HD) CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2006
IN-CENTER HEMODIALYSIS (HD) CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2006 PATIENT IDENTIFICATION [Before completing please read instructions at the bottom of this page and on pages 5 and 6] MAKE
More informationPrevalence of complications in children with chronic kidney disease according to KDOQI
http://www.kidney-international.org & 2006 International Society of Nephrology original article Prevalence of complications in children with chronic kidney disease according to DOQI H Wong 1, Mylrea 1,
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Biochemical Targets. Calcium GUIDELINES
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Biochemical Targets CARMEL HAWLEY (Woolloongabba, Queensland) GRAHAME ELDER (Westmead, New South Wales) Calcium GUIDELINES
More informationFULFILLMENT OF K/DOQI GUIDELINES 92 anemia treatment dialysis therapy vascular access
INTRODUCTION ANEMIA TREATMENT hemoglobin levels epo treatment iron treatment FULFILLMENT OF K/DOQI GUIDELINES 2 anemia treatment dialysis therapy vascular access EPO DOSING PATTERNS 4 epo dosing per kg
More informationOptions in Renal Replacement Therapy: When, whom, which? Prof Dr. Serhan Tuğlular Marmara University Medical School Division of Nephrology
Options in Renal Replacement Therapy: When, whom, which? Prof Dr. Serhan Tuğlular Marmara University Medical School Division of Nephrology CKD Classification Stage Description GFR (ml/min/1.73.m2) 1 Kidney
More informationHypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town
Hypertension targets: sorting out the confusion Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Historical Perspective The most famous casualty of this approach was the
More informationUse of Acute Kidney Injury Biomarkers in Clinical Trials
Use of Acute Kidney Injury Biomarkers in Clinical Trials Design Considerations Amit X. Garg MD, MA (Education), FRCPC, PhD Nephrologist, London Health Sciences Centre Professor, Medicine and Epidemiology
More information